ECTRIMS-ACTRIMS 2020 Late Breaking News: Encore Session, Sept 26th
The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research...
Read More
MS
ACTRIMS-ECTRIMS: Thyroid Disorders Don’t Affect MS Control
Thyroid AEs did not diminish alemtuzumab efficacy Adverse thyroid events occur frequently among...
Read More
ACTRIMS-ECTRIMS: Advantages Seen for Ozanimod over Teriflunomide
Safety modeling favors ozanimod Patients diagnosed with multiple sclerosis appear to have fewer...
Read More
ACTRIMS-ECTRIMS: Alemtuzumab Slows Brain Atrophy in MS Patients
Benefit observed in patients with or without disease activity Among multiple sclerosis patients...
Read More
MSVirtual2020: Anticipated Efficacy Results from Phase IV MAGNIFY-MS Study
Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined...
Read More
Upcoming MSVirtual2020: Virtual Joint ACTRIMS-ECTRIMS Meeting
MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis...
Read More
ACTRIMS-ECTRIMS: Anticipated Results from ASCLEPIOS Phase III
New efficacy and safety data on ofatumumab (Kesimpta), the first and only self-administered,...
Read More
ACTRIMS-ECTRIMS: Progressive Forms of MS and Disease-Modifying Therapies
Health Union has been accepted to present research, in the form of two poster presentations,...
Read More
ACTRIMS-ECTRIMS: The Potential of Brain-Penetrant BTK Inhibitors
This year, MSVirtual2020 (ACTRIMS/ECTRIMS) congress will feature new data relating to tolebrutinib...
Read More
ACTRIMS-ECTRIMS: Program at a Glance
Download the MSVirtual2020 Program at a Glance schedule (PDF)
Read More- 1
- 2